...
首页> 外文期刊>Pediatric radiology >Radiation dose reduction during intra-arterial chemotherapy for retinoblastoma: a retrospective analysis of 96 consecutive pediatric interventions using five distinct protocols
【24h】

Radiation dose reduction during intra-arterial chemotherapy for retinoblastoma: a retrospective analysis of 96 consecutive pediatric interventions using five distinct protocols

机译:视网膜母细胞瘤中动脉内化疗过程中的辐射剂量降低:使用五种不同方案的96个连续儿科干预的回顾性分析

获取原文
获取原文并翻译 | 示例

摘要

Background Intra-arterial chemotherapy (IAC) represents a mainstay of retinoblastoma treatment in children. Patients with retinoblastoma are uniquely at risk for secondary malignancies and are sensitive to the ionizing effects of radiation. Objective To retrospectively review a single institution's experience with IAC for retinoblastoma and the effect of variable intra-procedural imaging techniques on radiation exposure. Materials and methods Twenty-four consecutive patients, with a mean age of 30.8 +/- 16.3 months (range: 3.2-83.4 months), undergoing IAC for retinoblastoma between May 2014 and May 2020 (72 months) were included. No patients were excluded. The primary outcome was radiation exposure and secondary outcomes included technical success and procedural adverse events. Technical success was defined as catheterization of the ophthalmic or meningolacrimal artery and complete delivery of chemotherapy. Each procedure was retrospectively reviewed and categorized as one of five imaging protocol types. Protocol types were characterized by uniplanar versus multiplanar imaging and digital subtraction angiographic versus roadmap angiographic techniques. Radiation exposure, protocol utilization, the association of protocol and radiation exposure were assessed. Results During 96 consecutive interventions, 109 ocular treatments were performed. Thirteen of the 96 (15.5%) treatments were bilateral. Ocular technical success was 106 of 109 (97.2%). All three treatment failures were successfully repeated within a week. Mean fluoroscopy time was 6.4 +/- 6.2 min (range: 0.7-31.1 min). Mean air kerma was 36.2 +/- 52.2 mGy (range: 1.4-215.0 mGy). There were two major (1.8%) complications and four (3.7%) minor complications. Of the 96 procedures, 10 (10.4%), 9 (9.4%), 13 (13.5%), 28 (29.2%) and 36 (37.5%) were performed using protocol types A, B, C, D and E, respectively. For protocol type A, mean fluoroscopy time was 10.3 +/- 6.8 min (range: 3.0-25.4 min) and mean air kerma was 118.2 +/- 61.2 mGy (range: 24.5-167.3 mGy). For protocol type E, mean fluoroscopy time was 3.1 +/- 3.2 min (range: 0.7-15.1 min) and mean air kerma was 5.4 +/- 4.2 mGy (range: 1.4-19.5 mGy). Fluoroscopy time and air kerma decreased over time, corresponding to the reduced use of multiplanar imaging and digital subtraction angiography. In the first quartile (procedures 1-24), 8 (33.3%), 7 (29.2%), 2 (8.3%), 6 (25.0%) and 1 (4.2%) were performed using protocol types A, B, C, D and E, respectively. Mean fluoroscopy time was 10.5 +/- 8.2 min (range: 2.4-28.1 min) and mean air kerma was 84.2 +/- 71.6 mGy (range: 12.8-215.0 mGy). In the final quartile (procedures 73-96), 24 (100%) procedures were performed using protocol type E. Mean fluoroscopy time was 3.5 +/- 4.0 min (range: 0.7-15.1 min) and mean air kerma was 5.0 +/- 4.3 mGy (range: 1.4-18.0 mGy), representing 66.7% and 94.1% reductions from the first quartile, respectively. Technical success in the second half of the experience was 100%. Conclusion Sequence elimination, consolidation from biplane imaging to lateral-only imaging, and replacing digital subtraction with roadmap angiography dramatically reduced radiation exposure during IAC for retinoblastoma without adversely affecting technical success or safety.
机译:背景动脉内化疗(IAC)是儿童视网膜母细胞瘤治疗的主要手段。视网膜母细胞瘤患者具有继发恶性肿瘤的独特风险,并且对辐射的电离效应敏感。目的回顾性分析单个机构应用IAC治疗视网膜母细胞瘤的经验,以及不同术中成像技术对辐射暴露的影响。材料与方法包括2014年5月至2020年5月(72个月)连续24例视网膜母细胞瘤患者,平均年龄30.8+/-16.3个月(范围:3.2-83.4个月)。未排除任何患者。主要结果是辐射暴露,次要结果包括技术成功和程序不良事件。技术上的成功被定义为眼动脉或脑膜泪道动脉插管和化疗的完成。对每种手术进行回顾性分析,并将其分为五种成像方案类型之一。协议类型以单平面与多平面成像、数字减影血管造影与路线图血管造影技术为特征。评估辐射暴露、方案利用、方案与辐射暴露的相关性。结果在96次连续干预中,共进行了109次眼部治疗。96例治疗中有13例(15.5%)为双侧。眼部技术成功率为106/109(97.2%)。三次治疗失败均在一周内成功重复。平均透视时间为6.4+/-6.2分钟(范围:0.7-31.1分钟)。平均空气比释动能为36.2+/-52.2 mGy(范围:1.4-215.0 mGy)。主要并发症2例(1.8%),次要并发症4例(3.7%)。在96项手术中,10项(10.4%)、9项(9.4%)、13项(13.5%)、28项(29.2%)和36项(37.5%)分别采用A、B、C、D和E类方案。对于方案类型A,平均透视时间为10.3+/-6.8分钟(范围:3.0-25.4分钟),平均空气比释光系数为118.2+/-61.2 mGy(范围:24.5-167.3 mGy)。对于方案类型E,平均荧光透视时间为3.1+/-3.2分钟(范围:0.7-15.1分钟),平均空气比释动能为5.4+/-4.2 mGy(范围:1.4-19.5 mGy)。随着时间的推移,透视时间和空气比释光系数降低,与多平面成像和数字减影血管造影的使用减少相对应。在第一个四分位数(程序1-24)中,分别使用A、B、C、D和E类方案进行了8次(33.3%)、7次(29.2%)、2次(8.3%)、6次(25.0%)和1次(4.2%)。平均荧光透视时间为10.5+/-8.2分钟(范围:2.4-28.1分钟),平均空气比释动能为84.2+/-71.6 mGy(范围:12.8-215.0 mGy)。在最后一个四分位数(程序73-96)中,使用方案类型E执行了24(100%)个程序。平均透视时间为3.5+/-4.0分钟(范围:0.7-15.1分钟),平均空气比释动能为5.0+/-4.3 mGy(范围:1.4-18.0 mGy),分别比第一个四分位数减少66.7%和94.1%。下半年的技术成功率为100%。结论:序列消除、从双平面成像巩固到仅侧面成像,以及用路线图血管造影代替数字减影,可显著减少视网膜母细胞瘤IAC期间的辐射照射,而不会对技术成功或安全性产生不利影响。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号